Amyloid β1–42 Oligomers Induce Galectin–1S8 O–GlcNAcylation Leading to Microglia Migration

Protein O–GlcNAcylation has been associated with neurodegenerative diseases such as Alzheimer’s disease (AD). The O–GlcNAcylation of the Amyloid Precursor Protein (APP) regulates both the trafficking and the processing of the APP through the amyloidogenic pathway, resulting in the release and aggregation of the Aβ1–42 peptide. Microglia clears Aβ aggregates and dead cells to maintain brain homeostasis. Here, using LC-MS/MS, we revealed that the Aβ1–42 oligomers modify the microglia O-GlcNAcome. We identified 55 proteins, focusing our research on Galectin-1 protein since it is a very versatile protein from a functional point of view. Combining biochemical with genetic approaches, we demonstrated that Aβ1–42 oligomers specifically target Galectin–1S8 O–GlcNAcylation via OGT. In addition to this, the Gal–1–O–GlcNAcylated form, in turn, controls human microglia migration. Given the importance of microglia migration in the progression of AD, this study reports the relationship between the Aβ1–42 oligomers and Serine 8–O–GlcNAcylation of Galectin–1 to drive microglial migration.


Introduction
Protein O-GlcNAcylation is a dynamic posttranslational modification (PTM) that occurs on thousands of nucleocytoplasmic and mitochondrial proteins that control important cellular processes such as transcription, translation, metabolism or signal transduction [1,2]. O-GlcNAcylation in proteins occurs at serine and threonine residues, which, in turn, could also be phosphorylated. In an unbalanced situation, one PTM could be favored at the expense of the other [3]. Thus, disruptions in the O-GlcNAcylation/phosphorylation balance have been associated with cancer [4], neurodevelopmental disorders [5], and neurodegeneration, such as Alzheimer's Disease (AD) [6][7][8]. Regarding AD, different studies have demonstrated that in this pathology, some proteins are hyper-O-GlcNAcylated while others lose their O-GlcNAcylation [6][7][8][9].

Production and Purification of Amyloid-β 1-42 (Aβ 1-42 ) and Oligomers Preparation
The production and purification of Aβ 1-42 oligomers were based on [20] with some modifications. Bacterial cultures were grown overnight in 10 mL 2XYT media with 100 µg/mL of ampicillin at 37 • C and at 220 rpm. After approximately 16 h, the bacterial cultures were diluted to 1:10 and incubated at 30 • C for 3 h at 235 rpm. After the incubation, protein expression was induced with 1 mM IPTG at 13 • C for 24 h at 235 rpm. Finally, the bacterial suspension was centrifuged at 4500 rpm for 10 min, and the supernatant was discarded. The pellet was resuspended in 10 mL of buffer A (10 mM Tris-HCl pH 8, 1 mM EDTA). The bacterial suspension was sonicated for 2 min on ice in a UP100H Ultrasonic Processor (Hielscher, Oderstraße 53, 14513 Teltow, Germany) with 1 2 horn and 50% duty cycle. This solution was then centrifuged at 18,000× g for 10 min at 4 • C, and the supernatant was discarded. The pellet containing the inclusion bodies was resuspended in a 10 mL buffer. It was subjected to other 2 cycles of sonication, centrifugation and resuspension in buffer A. After 3 whole cycles, the last pellet was resuspended in 5 mL of 8 M urea in buffer A, and the solution was incubated on ice for 15 min. After that period, the solution containing urea-solubilized inclusion bodies was sonicated and centrifuged, and finally, the supernatant containing the Aβ 1-42 peptide was collected and diluted with 15 mL buffer A. The Aβ 1-42 peptide was then purified by ion exchange chromatography in a NGC Quest 10 Liquid Chromatography System (Life Science, 1000 Alfred Nobel Drive, Hercules, CA 94547, USA). The Bio-Scale TM Mini UNOsphere TM Q Cartridge (Life Science) column was first equilibrated with buffer A. The 20 mL sample containing Aβ 1-42 peptide was then loaded onto the column. The column was washed with buffer A, and the protein was eluted by ion exchange with a gradient of 0 to 300 mM NaCl in buffer A. The eluted fractions containing the Aβ 1-42 peptide was collected and subjected to another purification and concentration protocol. These fractions were passed through a 30 kDa molecular mass cut-off filter Amicon Ultra-15 membrane PLTK Ultracel-PL 30 kDa (Merck KGAA) in order to remove proteins that were bigger than 30 kDa. For this purpose, the filter was first washed with H 2 O at 4000× g for 20 min. Then, the protein solution was added, and it was centrifuged at 4000× g for 20 min. The fraction that passed the filter (≤30 kDa) was collected. The ≤30 kDa solution was passed through a 3 kDa molecular mass cut-off filter Amicon Ultra-15 membrane PLBC Ultracel-PL 3 kDa (Merck KGAA) to discard the proteins that were smaller than 3 kDa. For this second purification step, the filter was first washed with H 2 O at 4000× g for 30 min, and then, the ≤30 kDa solution was added and centrifuged at 4000× g for 60 min. We discarded the solution that passed the filter (≤3 kDa). In order to remove the salt coming from the chromatography of the solution containing Aβ 1-42 monomers, we added miliQ H 2 O to the fraction, which did not pass the filter, and we centrifuged it at 4000× g. After 60 min, the fraction that had not passed the filter was collected, which was concentrated in approximately 400 µL of H 2 O.
The filtered volume was then lyophilized In a Virtis Lyophilizer (Millrock Technology, Inc., 39 Kieffer Lane, Kingston, NY 12401, USA) overnight. After approximately 18 h, the lyophilized Aβ 1-42 peptide was weighted. After that, stock peptide films of the Aβ 1-42 peptide were prepared based on the protocol reported by Klein [21]. Briefly, the lyophilized Aβ 1-42 peptide was solubilized in cold HFP at a final peptide concentration of 1 mM. The solubilization process was carried out in an Actor Ultrasonic Bath (Lovango, Pintor Roig i Soler, 14, 08916 Badalona, Spain) for approximately 2 h until the solution turned clear and colorless. Finally, the solution was aliquoted, and the HFP was left to evaporate in the fume hood for 1 h. Once evaporated, the tubes were transferred to a SpeedVac SC110 Vacuum Concentrator (Thermo Fisher Scientific, 168 Third Avenue, Waltham, MA, USA) and dried down for 10 min, obtaining a thin clear peptide film at the bottom of the tubes. The aliquots were kept at −80 • C until use. The day before the experiments, one aliquot of the peptide film was dissolved in 5 mM of DMSO in Ham's F12 medium in a volume such that the final peptide concentration was 100 µM. The solution was left for 18 h at 4 • C in order to form the globular oligomers, also known as amyloid β-Derived Diffusible Ligands (ADDL).

Cell Culture
Immortalized human microglia (Cat no T0251, Applied Biological Materials Inc. #1-3671 Viking Way, Richmond, BC V6V 2J5, Canada) were cultured in DMEM high-glucose, supplemented with 10% FBS and 100 U/mL of penicillin and 100 µg/mL of streptomycin. Cells were seeded in plates that had previously been coated with 0.01% (v/v) collagen type I and incubated at 37 • C in an atmosphere with 5% CO 2 . For the experiments, cells were washed 3 times with PBS before being deprived of 1% FBS for 24 h. On the day of the experiments, the cells were untreated or treated with 5 µM Aβ 1-42 oligomers as described [23]. To examine the effects of OSMI-I and Thiamet G, these inhibitors were added at 25 µM and 10 µM, respectively, for 16 h before their stimulation with Aβ 1-42 oligomers.

Microglia Transient Transfection
Microglia were washed twice with PBS and resuspended in DMEM high glucose without FBS. The 4 × 10 6 cells/200 µL medium were then transferred to an electroporation cuvette of 0.4 cm (Merck KGAA) containing between 5 and 10 µg cDNA of interest as indicated in the Section 3. The electroporation was carried out at 260 V and 950 µF in a Gene Pulser Xcell TM electroporator (Life Science) [24]. After that, electroporated cells were collected, and DMEM with FBS was added. The transfected cells were incubated for 48 h in the incubator at 37 • C before the experiments [24]. Microglia were also transfected with Lipofectamine TM 3000 (Thermo Fisher Scientific) according to the manufacturer's instructions 48 h prior to the experiments.

Wheat Germ Agglutinin-Affinity Precipitation and Protein Identification by LC-MS/MS
The cells were either stimulated or not with 5 µM Aβ 1-42 oligomers at 37 • C for 30 min [23,25] and washed twice with cold PBS. Next, the cells were lysed with a RIPA buffer (50 mM Tris-HCl pH 7.4, 1% IGEPAL ® CA-630, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM Na 3 VO 4 , 1 mM NaF and protease inhibitor cocktail ((P8340) from Merck KGAA) for 20 min at 4 • C in an orbital shaker. Then, the lysates were centrifuged at 13500 rpm for 10 min at 4 • C, and the supernatants (500 µg protein) were incubated with previously washed WGA-agarose beads for 1 h at 4 • C in an orbital shaker. After that, the complexes were washed three times with a binding buffer at 4000 rpm for 1 min at 4 • C. The O-GlcNAcylated proteins were dissociated from the WGA-agarose beads by the addition of SDS sample loading buffer (Merck KGAA, Reference 70607) and samples were analyzed by SDS-PAGE.
For the O-GlcNAcylated proteomic analysis, 6.4 × 10 7 cells and WGA-agarose beads were used. After purification, the O-GlcNAcylated proteins were eluted from the complexes by the addition of 20 mM GlcNAc in a binding buffer for 10 min at 4 • C in an orbital shaker. The samples were then centrifuged at 4000 rpm for 1 min at 4 • C, and the supernatants (3 mg protein per condition) were collected and analyzed by LC-MS/MS in the Proteomics General Service (SGIker) of the University of the Basque Country (UPV/EHU). The Q Exactive mass spectrometer (Thermo Scientific) coupled to the Easy-nLC 1000 nanoUPLC System (Thermo Scientific) chromatograph was used. The resulting spectra were processed with a Proteome Discoverer 1.4 (Thermo Scientific). Swiss-Prot human database, which was used for peptide identification.
WGA purification was also used for the specific analysis of Gal-1 O-GlcNAcylation. Microglia were transfected with 10 µg of either a plasmid encoding for mDsRed-Gal-1 or mDsRe-Gal-1 S8A by electroporation. Cells were serum-deprived for 24 h and were either stimulated or not with 5 µM Aβ 1-42 oligomers for 30 min. Lysates (500 µg protein) were obtained in the RIPA buffer containing the OGA inhibitor Thiamet G, and O-GlcNAcylated proteins were purified with WGA-agarose beads at 4 • C. The affinity complexes were then washed three times with RIPA + Thiamet G, and the proteins were eluted. The eluted proteins and the total input fractions were analyzed by SDS-PAGE, and the presence of Gal-1 was determined by a Western blot; proteins were transferred to PVDF membranes (Life Science) and then were blocked with 5% milk in TBST before finally being blotted using a specific anti-DsRed antibody (Takara Bio Europe SAS, 34 rue de la Croix de fer, 78100 Saint-Germain en Laye, France. Reference 632496, dilution 1:1000. Antibodies were incubated for 1 h at RT).

In Vitro O-GlcNAcTransferase (OGT) Assay
The in vitro OGT assay from microglia was based on [26]. Briefly, microglia were transfected with pDest-N-Myc-OGT by electroporation. After 24 h, transfected cells were serum-deprived for an additional 24 h. On the day of the experiment, the cells were either stimulated or not with 5 µM Aβ 1-42 oligomers for 30 min, and they were lysed with a RIPA buffer containing the O-GlcNAcase (OGA) inhibitor (10 µM Thiamet G). In total, 500 µg of protein per condition were incubated for 2 h at 4 • C with anti-Myc antibody bound to protein A-Sepharose beads. Immunocomplexes were washed, and the transferase reaction was made by adding 100 µL of 1 mM UDP-GlcNAc and 500 ng GST-Gal-1 as the substrates. The reaction was incubated at 37 • C for 3 h and was stopped by the addition of SDS sample loading buffer (Merck KGAA, Reference 70607). The proteins were separated by SDS-PAGE and OGT activity and measured by analyzing GST-Gal-1 O-GlcNAcylation by SDS-PAGE and Western blot. The proteins were transferred to PVDF membranes (Life Science) before being blocked with 5% milk in TBST and finally blotted using specific antibodies: anti-O-GlcNAc (Merck KGAA, reference 05-1245, dilution 1:1000, anti-GST (Merck KGAA, reference G7781, dilution 1:50,000) and anti-Myc (Merck KGAA, reference M4439, dilution 1:5000. Antibodies were incubated for 1 h at RT).

Scratch Wound Healing Assay
Scratch wound healing was performed based on [27]. The cells were seeded 24 h prior to the experiment and were serum-deprived with 1% FBS and the experiment was conducted in this serum-free medium to ensure that there was no proliferation during the migration assay. A scratch was performed on the cell monolayer, and cells were either stimulated or not with 5 µM Aβ 1-42 oligomers. In experiments with inhibitors, these compounds were added 16 h prior to the stimulation, as indicated in the Section 3. Photographs of the wound were taken in four random fields with the 4× objective in an EVOS™ Digital Color Fluorescence Microscope (Life Science) at the beginning of the experiment and after 24 h of incubation at 37 • C. The percentage of migration was calculated in the Fiji-ImageJ by measuring the width of the wound before (0 h) and after (24 h) the cells had migrated.

Transwell Migration Assay
A transwell assay was conducted based on [27] using the Costar Transwell System with an 8-µm pore size polycarbonate membrane (Merck KGAA). In total, 250,000 human microglia cells were serum-deprived with 1% FBS for 24 h, which were seeded in the upper chamber for the 200 µL serum-free medium and in the presence or the absence of 5 µM Aβ 1-42 oligomers. In total, 600 µL of the serum-free medium was placed in the lower chamber. The cells were incubated for 24 h at 37 • C. The microglia that had not migrated were removed from the upper side of the membrane with a cotton swab, and cells that had migrated to the lower side were fixed with 4% PFA for 10 min. Migrated cells were then stained with Mayer's Hematoxylin for 20 min. Four randomly chosen areas were photographed with the 10× objective in an EVOS™ Digital Color Fluorescence Microscope (Life Science), and these cells were counted in Fiji-ImageJ (National Institutes of General Medical Sciences, 45 Center Drive MSC 6200, Bethesda, MD 20892-6200, USA) in order to calculate the percentage of migrating cells.

Aβ 1-42 Oligomers Increase Protein O-GlcNAcylation in Human Microglia
Firstly, we investigated if the protein O-GlcNAcylation pattern was modified in the presence of Aβ 1-42 oligomers in human microglia. For this, 1 × 10 7 cells were treated or not with 5 µM Aβ 1-42 oligomers for 30 min before being washed and lysed. Then, O-GlcNAcylated proteins were purified with wheat germ agglutinin (WGA) agarose beads and analyzed by SDS-PAGE followed by Western blotting. WGA-purified proteins from Aβ 1-42 oligomers-stimulated microglia showed an increased O-GlcNAcylation pattern ( Figure 1A, lane 2 compared to lane 1). The total lysates (input) were used as an internal control ( Figure 1A, lanes 3, 4). The quantification of three independent experiments demonstrated that the stimulation resulted in a 1 ± 0-fold increase in the microglial protein O-GlcNAcylation compared to the untreated control ( Figure 1A, bar graph).
These results prompted us to identify the specific proteins that were differentially O-GlcNAcylated in the Aβ 1-42 oligomers-stimulated microglia. With this purpose, the cells were either stimulated or not with 5 µM Aβ 1-42 oligomers for 30 min, and O-GlcNAcylated proteins were purified and analyzed by LC-MS/MS as described in the Section 2. As shown in the Venn diagram of Figure 1B, the results from LC-MS/MS identified 44 proteins in untreated cells, where 55 proteins were identified in the Aβ 1-42 oligomers-stimulated cells with 182 proteins in both conditions ( Figure 1B and Table S1).
Of these 55 proteins, Galectin-1 (Gal-1) was chosen among several others owing to its functional versatility. In fact, Gal-1 controls many signaling cascades both in an intra-and extracellular manner, with potential implications in the control of microglial migration [28,29]. Analyzing the specific peptides of Gal-1 obtained by LC-MS/MS, one of them was the ACGLVASNLNLKPGECLR peptide. This peptide was located at the Nterminal from aa 2 to aa 19 and contained a serine, Ser 8 , which could be O-GlcNAcylated. This result suggested that the O-GlcNAcylation in this specific Ser could play an important role in the function of the protein.
Next, we examined whether Aβ 1-42 oligomers induced Gal-1 O-GlcNAcylation in human microglia and secondly verified if this PTM occurred on Ser 8 . Therefore, microglia were transfected with 10 µg of either a plasmid encoding for mDsRed-Gal-1 or mDsRed-Gal-1 S8A by electroporation and Gal-1 O-GlcNAcylation was analyzed as indicated in the Section 2. As shown in Figure 1C Regarding the mutated Gal-1, our results indicated that the exchange of the Ser 8 by Ala resulted in a strong decrease in the Gal-1 O-GlcNAcylation. Without Aβ 1-42 oligomers stimulation, the O-GlcNAcylation levels were similar to the Gal-1 WT in non-stimulated cells (1 ± 0), and in the presence of Aβ 1-42 oligomers, the levels were 1 ± 0. Thus, Aβ 1-42 oligomers were not able to induce an increase in O-GlcNAcylation in Gal-1 S8A . Altogether, our findings suggest that Aβ 1-42 oligomers mediate the Ser 8 O-GlcNAcylation of Gal-1 in human microglia.
Given that Aβ 1-42 oligomers resulted in a rise in the microglial protein O-GlcNAcylation, with Gal-1 being among these proteins, our next goal was to investigate whether Aβ 1-42 oligomers produced an increase in OGT enzymatic activity towards Gal-1. This was measured by an in vitro OGT activity assay.
O-GlcNAcylated Gal-1 ( Figure 1D, upper panel) was normalized with the total Gal-1 ( Figure 1D, middle panel). Western blot with an anti-Myc antibody confirmed the immunoprecipitation of the enzyme OGT ( Figure 1D, lower panel). Quantitatively, in the presence of Aβ1-42 oligomers, OGT was two-fold as active as in the non-stimulated conditions. The quantification of the Western blot demonstrated a fold change of 2 ± 0 compared to the control ( Figure 1D).  proteins that were identified exclusively in each group and the number of proteins that were common in both groups. The Venn diagram was representative of three independent experiments, with the difference in proteins identified between them being ±5. (C) Microglia were transfected either with mDsRed-Gal-1 or mDsRed-Gal-1 S8A and were stimulated with 5 µM Aβ 1-42 oligomers, and O-GlcNAcylated proteins were purified with WGA-agarose beads. Free GlcNAc was added as a control for specificity in the purification. Purified and total input fractions were analyzed by SDS-PAGE and Western blot. The blot was representative of three independent experiments (N = 3), and the bar graph represents the mean ± S.E.M. of each WGA-purified condition, normalized by their corresponding total input, compared to the nonstimulated control. Mann-Whitney statistical analysis showed a significant difference. *** p < 0.001; ### p < 0.001. (D) Myc-OGT was transfected in microglia, where they were stimulated with 5 µM Aβ 1-42 oligomers, and immunoprecipitation was performed with α-myc. Substrates UDP-GlcNAc and GST-Gal-1 were added to the complexes, and the O-GlcNAcylation reaction was incubated. OGT activity was visualized by SDS-PAGE and Western blot. The blot was representative of three independent experiments (N = 3). An antibody α-O-GlcNAc was used for analyzing OGT activity; an antibody α-GST was used in order to check the total substrate; an antibody α-myc was used in order to confirm the immunoprecipitation efficiency. O-GlcNAcylated Gal-1 was normalized by its corresponding total substrate (α-GST) in each condition. These normalized values were compared to the non-stimulated control (fold change). The bar graph represents the fold change means ± S.E.M. of each condition. Mann-Whitney statistical analysis showed a significant difference * p < 0.05. Figure 1D, Aβ 1-42 oligomers mediated OGT activation, which was measured as an increase in the O-GlcNAcylation of its substrate Gal-1. For the quantification, O-GlcNAcylated Gal-1 ( Figure 1D, upper panel) was normalized with the total Gal-1 ( Figure 1D, middle panel). Western blot with an anti-Myc antibody confirmed the immunoprecipitation of the enzyme OGT ( Figure 1D, lower panel). Quantitatively, in the presence of Aβ 1-42 oligomers, OGT was two-fold as active as in the non-stimulated conditions. The quantification of the Western blot demonstrated a fold change of 2 ± 0 compared to the control ( Figure 1D).

O-GlcNAc Homeostasis Controls Aβ 1-42 -Induced Microglial Migration
Taking into account that OGT mediated the O-GlcNAcylation of Gal-1, a protein implicated in cellular migration, we investigated whether O-GlcNAcylation regulates microglia migration. This was analyzed by a scratch wound healing assay using the OGT inhibitor OSMI-I [28] and the OGA inhibitor Thiamet G [29]. Briefly, 8 × 10 5 cells were seeded in a 6-well plate per well 48 h prior to the experiment and were then serum-starved for 24 h. On the day of the experiment, 25 µM of OSMI-I and 10 µM of Thiamet G or DMSO (as a vehicle) were added overnight. Next, a scratch was performed in the cell monolayer, and 5 µM Aβ 1-42 oligomers were added in the corresponding wells. As expected, after 24 h in the presence of Aβ 1-42 oligomers, they produced a strong increase in microglia migration ( Figure 2D) compared to time 0 ( Figure 2B), which resulted in a 440 ± 30% increase in migration compared to the control ( Figure 2M). This vehicle (DMSO) did not alter migration. Regarding the effect of OSMI-I, this compound reduced basal microglia migration ( Figure 2G), and OSMI-I abolished the Aβ 1-42 oligomers-dependent increase in microglial migration ( Figure 2H compared to Figure 2D). The migration rate was 41 ± 9% in the presence of OSMI-I and, in the absence of Aβ 1-42 oligomers ( Figure 2M), the addition of amyloid beta did not affect the migration of OSMI-treated cells (41 ± 9%, Figure 2M). On the contrary, the OGA inhibitor Thiamet G provoked a substantial increase in microglia migration. In fact, when cells were not stimulated with the Aβ 1-42 oligomers, migration reached 539 ± 53% ( Figure 2K,M). This was similar when the Aβ 1-42 oligmers was added to microglia, which resulted in an increase in migration by 550 ± 66% ( Figure 2L,M).
In order to verify these results, the effect of O-GlcNAcylation on microglia migration was analyzed by a transwell assay. In total, 250,000 cells were seeded in the upper well of the transwell chamber, they were treated with OSMI-I, Thiamet G or DMSO for 1 h followed by 5 µM Aβ 1-42 oligomers, and 24 h of microglia migration was examined. The Aβ 1-42 oligomers increased microglia migration (5517 ± 45%) ( Figure 3B) compared to the control cells ( Figure 3A). Again, OSMI-I completely blocked microglial migration induced by Aβ 1-42 oligomers. From a quantitative point of view, the migration rate was 108 ± 13% ( Figure 3D,G) and 88 ± 11% ( Figure 3C,G) with and without Aβ 1-42 oligomers' stimulation, respectively. As expected, Thiamet G provoked an uncontrolled migration, even in the absence of Aβ 1-42 oligomers, where the migration rate was 5737 ± 65% ( Figure 3E,F), and the presence of Aβ 1-42 oligomers did not modify this rate 5665 ± 165% ( Figure 3F,G). These findings suggest that protein O-GlcNAcylation could control microglia migration.

O-GlcNAc Homeostasis Controls Aβ 1-42 Oligomers-Induced Microglial Migration through Galectin-1 Ser 8 O-GlcNAcylation
The OGT inhibitor, OSMI-I, reduced global O-GlcNAcylation in cells and affected cell viability [26]. Taking into account that we had identified by LC/MS the Gal-1 ACGLVASNLNLKPGECLR peptide susceptible to O-GlcNAcylated in Serine 8, we generated and purified the TAT-OGT binding domain-Gal-1 (TAT-OBD-Gal-1) peptide. This permeant peptide interfered in the natural interaction between the OGT and Gal-1, blocking the Gal-1 O-GlcNAcylation and downstream signaling pathway.
Briefly, immortalized human microglia (800,000 cells/well) were seeded in 6-well plates 48 h prior to the experiment. These cells were serum-starved for 24 h. Then, they were treated with 25 µg of either the TAT-EGFP control peptide or 25 µg of TAT-OBD-Gal-1 for one hour. A scratch was performed in the cell monolayer with 5 µM Aβ 1-42 oligomers, which were added, and images were taken at 0 h and 24 h of migration. As shown in Figure 4, TAT-EGFP-treated cells responded to Aβ 1-42 oligomers by increasing their migration to 1225 ± 16% ( Figure 4D,I) compared to control, which was expressed as 100% ( Figure 4C,I). On the contrary, TAT-OBD-Gal-1 treatment completely blocked microglia migration. In fact, the migration rate was 138 ± 15% without Aβ 1-42 oligomers stimulation ( Figure 4G,I), which was similarly maintained at 127 ± 41% with the Aβ 1-42 oligomers ( Figure 4H,I).
Next, a transwell assay was performed with TAT-EGFP and TAT-OBD-Gal-1 peptides. In this regard, serum-deprived immortalized human microglia were seeded in the upper well of the transwell chamber (250,000 cells per condition), where they were treated with 25 µg of either the TAT-EGFP control peptide or 25 µg of TAT-OBD-Gal-1 for one hour followed by 5 µM Aβ 1-42 oligomers. Migration was analyzed 24 h later. As shown in Figure 5, TAT-EGFP-treated cells responded to Aβ 1-42 oligomers by increasing their migration significantly to 732 ± 25% ( Figure 5B,E) compared to non-stimulated cells ( Figure 5A,E). On the contrary, TAT-OBD-Gal-1 completely blocked microglia migration. These microglia migrated 84 ± 14% without the stimulation of Aβ 1-42 oligomers ( Figure 5C,E) which was similarly maintained at 95 ± 8% with Aβ 1-42 oligomers ( Figure 5D,E). Altogether, these results suggested that Aβ 1-42 oligomers could involve the tandem of OGT/Gal-1 in microglia migration.   In order to examine the role of Gal-1 S8 O-GlcNAcylation in the control of microglia migration, human microglia were transfected with 10 µg of plasmids, encoding either mDsRed-Gal-1 wt or mDsRed-Gal-1 S8A (non-O-GlcNAc Gal-1) and 24 h later; these cells were serum-starved for 24 h. Then, a scratch was conducted in the cell monolayer, where microglia were either treated or not with 5 µM Aβ 1-42 oligomers, and migration was analyzed by taking images at 0 h and 24 h. As shown in Figure 6, microglia that had been transfected with Gal-1 wt responded to Aβ 1-42 oligomers (169 ± 3%) ( Figure 6D,I) compared to the control ( Figure 6C,I). Gal-1 S8A -transfected cells, however, resulted in an uncontrolled migration both in the absence (194 ± 5%, Figure 6G,I) and in the presence of Aβ 1-42 oligomers (193 ± 1%, Figure 6H,I). When we performed the microglia migration experiment in a transwell assay, the migration pattern was similar to the wound healing assay. Microglia that had been transfected with Gal-1 WT responded to Aβ 1-42 oligomers by migrating 1177 ± 136% ( Figure 7B,E) compared to the control ( Figure 7A,E). On the other hand, Gal-1 S8A -transfected cells presented an uncontrolled migration both in the absence (1936 ± 156%, Figure 7C,E) and in the presence of Aβ 1-42 oligomers (2274 ± 156%, Figure 7D,E).
Hence, our findings suggest that the Gal-1 Ser 8 O-GlcNAcylation fine-tuned microglial migration, and abolishing Gal-1 Ser 8 O-GlcNAcylation resulted in a hyper-migration phenotype in microglia, which was indicative of uncontrolled microglial migration. Overall, our data suggest that Aβ 1-42 oligomers regulated microglial migration through the modulation of Gal-1 Ser 8 O-GlcNAcylation. transfected cells presented an uncontrolled migration both in the absence (1936 ± 156%, Figure 7C,E) and in the presence of Aβ1-42 oligomers (2274 ± 156%, Figure 7D,E). Hence, our findings suggest that the Gal-1 Ser 8 O-GlcNAcylation fine-tuned microglial migration, and abolishing Gal-1 Ser 8 O-GlcNAcylation resulted in a hyper-migration phenotype in microglia, which was indicative of uncontrolled microglial migration. Overall, our data suggest that Aβ1-42 oligomers regulated microglial migration through the modulation of Gal-1 Ser 8 O-GlcNAcylation.

Discussion
The protein O-GlcNAcylation pattern is altered in the brains of AD patients, affecting myriad proteins, including synaptic, cytoskeleton and memory-associated proteins, all of which are relevant in the context of AD [6,8]. Accordingly, our study on microglia has revealed that Aβ1-42 oligomers provoke an increase in protein O-GlcNAcylation, and of the 55 proteins identified, we found Gal-1. In addition, LC/MS analysis suggested that the Gal-1 O-GlcNAcylation does occur on serine 8, verifying it both through biochemical and genetic approaches. The fact that Gal-1 is modified by the GlcNAc group points out that it could be an important PTM for cell biology [30][31][32][33]. In fact, we have demonstrated that this O-Glc-

Discussion
The protein O-GlcNAcylation pattern is altered in the brains of AD patients, affecting myriad proteins, including synaptic, cytoskeleton and memory-associated proteins, all of which are relevant in the context of AD [6,8]. Accordingly, our study on microglia has revealed that Aβ 1-42 oligomers provoke an increase in protein O-GlcNAcylation, and of the 55 proteins identified, we found Gal-1. In addition, LC/MS analysis suggested that the Gal-1 O-GlcNAcylation does occur on serine 8, verifying it both through biochemical and genetic approaches. The fact that Gal-1 is modified by the GlcNAc group points out that it could be an important PTM for cell biology [30][31][32][33]. In fact, we have demonstrated that this O-GlcNAcylation is relevant for migration in human microglia. Furthermore, we identified that the residue being modified is the Ser 8 from Gal-1. As a matter of fact, it is interesting to highlight that the Gal-1 was reported as phosphorylated at that same Ser 8 residue [34,35]. Taking into account that phosphorylation and O-GlcNAcylation could compete for the same residues, a disequilibrium between both PTMs could provoke the aberrant function of Gal-1 in microglia, in our case, in the context of AD. Aβ 1-42 oligomers could favor the balance towards O-GlcNAcylation as a detriment to phosphorylation. Hence, it would be interesting to investigate if AD patients present reduced phosphorylation, together with increased O-GlcNAcylation, in Gal-1. It would also be important to study whether this imbalance depends on the stage of the disease. We postulate that this imbalance towards Gal-1 O-GlcNAcylation could be happening at the initial stages, where microglia migration is increased. Thus, restoring the O-GlcNAcylation/phosphorylation equilibrium could be a therapeutic strategy in pathologies where this equilibrium is altered. In this regard, some investigations have conducted attempts with OGA inhibitors in order to increase tau protein O-GlcNAcylation and decrease phosphorylation [29,36]. Nevertheless, we believe that this approach should be specific to a particular protein. In fact, not all proteins present an equilibrium that is displaced towards O-GlcNAcylations in AD, as some of them are displaced towards phosphorylation [7,8,29,36,37].
Examining the functionality of O-GlcNAcylated Gal-1 induced by Aβ 1-42 oligomers in the control of microglia migration, our findings suggest that O-GlcNAcylated Gal-1 maintains this response in a controlled manner. On the contrary, when we mutated serine 8 to alanine, which prevented O-GlcNAcylation at this site, although we expected to block the microglia migration induced by Aβ 1-42 oligomers, this mutation led to a boost in the migration in an uncontrolled manner. This Gal-1 mutant behaved as if it was a constitutively active form. This increased migration could seem contradictory if we compare it with the inhibition of migration observed with the OGT inhibitor OSMI-I or the TAT-OBD-Gal-1 interfering peptide. The fact that OGT has a wide variety of substrates means that inhibiting its activity or using an interfering peptide could block the O-GlcNAcylation of many proteins rather than only Gal-1. Therefore, the response is different than when we specifically targeted the O-GlcNAcylation of Gal-1. Thus, in this paper, we have also described a peptide that could be blocking OGT activity.
Gal-1 is a protein that can function as a monomer or as a homodimer [30]. Its dimerization is essential to activating signaling cascades such as Ras/MAPK in the intracellular space [38] or CD45 phosphatase in the extracellular space [39]. We speculate that the presence of the GlcNAc group in Gal-1 favors its monomeric form over the dimeric form, while the S8A mutant facilitates Gal-1 homodimerization. Many functions of Gal-1 as a homodimer are related to its ability to function as a lectin by binding to glycoproteins of the cell membrane and components of the extracellular matrix [26], controlling cell responses such as proliferation, survival and inflammation in cancer or cell migration [30,40]. In the context of the central nervous system (CNS), it has been reported that astrocytes secrete Gal-1, which binds to CD45 glycoprotein in the microglia, to prevent the development of experimental autoimmune encephalomyelitis [39]. Nevertheless, these authors did not investigate if the microglia itself were able to secrete the Gal-1 protein and regulate its activation state through an autocrine mechanism. Future research needs to clarify whether O-GlcNAcylated Gal-1 is secreted and, secondly, whether it produces an autocrine/paracrine regulation in the microglia and other cell types in the CNS.

Conclusions
This study has revealed that in human microglia, Aβ 1-42 oligomers induce an increase in the protein O-GlcNAcylation and OGT activity towards Gal-1. Moreover, we identified that one of these proteins is Gal-1. The O-GlcNAcylation of Gal-1 in Ser 8 is key for Aβ 1-42 oligomers-induced microglia migration. In addition, we generated a Gal-1 (S8A) that behaved as a constitutively active form of Gal-1, absolutely dysregulating microglia migration. Given the importance of microglial migration in AD, we do not discard that Gal-1 could play an important role during the progression of AD, especially at the initial stages where microglia are recruited to the amyloid plaques.